Moderna, Inc.
MRNA
Ранг среди акций
#239
Moderna, Inc., a biotechnology firm, is dedicated to the discovery,... Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
Цена акции
$247.26
Рыночная капитализация
$98.72B
Изменение (1 день)
2.14%
Изменение (1 год)
799.45%
Страна
US
Торговля Moderna, Inc. (MRNA)
Категория
Healthcare
Выручка компании Moderna, Inc. (MRNA)
Выручка на Jun 2026 TTM: $2.23B
Согласно последним финансовым отчетам Moderna, Inc., текущая выручка компании (TTM) составляет $2.23B. В 2024 году компания получила выручку $3.20B меньше, чем выручке в 2023 году, которая составила $6.85B. Выручка — это общий доход, который компания получает от продажи товаров или услуг. В отличие от прибыли, расходы не вычитаются.
История выручки Moderna, Inc. с 2016 по 2026
Выручка на конец каждого года
| Год | Выручка | Изменить |
|---|---|---|
| 2026 (TTM) | $2.23B | 14.61% |
| 2025 | $1.94B | -39.23% |
| 2024 | $3.20B | -53.29% |
| 2023 | $6.85B | -63.72% |
| 2022 | $18.88B | 6.42% |
| 2021 | $17.74B | 2,107.63% |
| 2020 | $803.40M | 1,234.34% |
| 2019 | $60.21M | -55.42% |
| 2018 | $135.07M | -34.38% |
| 2017 | $205.83M | 89.88% |
| 2016 | $108.40M | 0.00% |
Выручка аналогичных компаний или конкурентов
| Компания | Выручка | Разница в выручке | Страна |
|---|---|---|---|
| $12.62B | 466.62% |
US
|
|
| $15.74B | 606.66% |
AU
|
|
| $6.02B | 170.26% |
NL
|
|
| - | - |
CH
|
|
| $10.11B | 353.81% |
BE
|
